Coût de la polyarthrite rhumatoïde en France : comparaison léflunomide/étanercept

This publication has 22 references indexed in Scilit:

• The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
  Health Technology Assessment, 2004
• Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards
  The European Journal of Health Economics, 2004
• Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries
  Annals of the Rheumatic Diseases, 2003
• Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources
  Annals of the Rheumatic Diseases, 2003
• Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden
  Annals of the Rheumatic Diseases, 2002
• Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine
  Scandinavian Journal of Rheumatology, 2001
• A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline
  Arthritis & Rheumatism, 1999
• Etanercept Therapy in Rheumatoid Arthritis
  Annals of Internal Medicine, 1999
• The total costs of drug therapy for rheumatoid arthritis
  Arthritis & Rheumatism, 1995